These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 3086274)

  • 41. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.
    Pedersen SS; Jensen T; Høiby N; Koch C; Flensborg EW
    Acta Paediatr Scand; 1987 Nov; 76(6):955-61. PubMed ID: 3425313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis.
    Martin AJ; Smalley CA; George RH; Healing DE; Anderson CM
    Arch Dis Child; 1980 Aug; 55(8):604-7. PubMed ID: 7436516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis unit.
    Denton M; Littlewood JM; Brownlee KG; Conway SP; Todd NJ
    Lancet; 1996 Dec; 348(9041):1596-7. PubMed ID: 8950918
    [No Abstract]   [Full Text] [Related]  

  • 44. Widespread detection of VEB-1-type extended-spectrum beta-lactamases among nosocomial ceftazidime-resistant Pseudomonas aeruginosa isolates in Sofia, Bulgaria.
    Strateva T; Ouzounova-Raykova V; Markova B; Todorova A; Marteva-Proevska Y; Mitov I
    J Chemother; 2007 Apr; 19(2):140-5. PubMed ID: 17434821
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.
    Lee AC; Jones AL
    Paediatr Respir Rev; 2018 Jun; 27():18-20. PubMed ID: 29914746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa?
    Watkins J; Francis J; Kuzemko JA
    Scand J Gastroenterol Suppl; 1988; 143():81-5. PubMed ID: 3133756
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
    Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
    Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.
    Kuti JL; Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP
    Diagn Microbiol Infect Dis; 2015 Sep; 83(1):53-5. PubMed ID: 26003469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isolation and treatment of cystic fibrosis patients with lung infections caused by Pseudomonas (Burkholderia) cepacia and multiresistant Pseudomonas aeruginosa.
    Høiby N
    Neth J Med; 1995 Jun; 46(6):280-7. PubMed ID: 7643943
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa.
    Deplano A; Denis O; Poirel L; Hocquet D; Nonhoff C; Byl B; Nordmann P; Vincent JL; Struelens MJ
    J Clin Microbiol; 2005 Mar; 43(3):1198-204. PubMed ID: 15750083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pseudomonas cepacia in cystic fibrosis patients.
    Prince A
    Am Rev Respir Dis; 1986 Oct; 134(4):644-5. PubMed ID: 3094414
    [No Abstract]   [Full Text] [Related]  

  • 52. Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis.
    Gaillard JL; Cahen P; Delacourt C; Silly C; Le Bourgeois M; Coustère C; de Blic J; Lenoir G; Scheinmann P
    Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):291-6. PubMed ID: 7649191
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical surveillance of surgical imipenem-resistant Pseudomonas aeruginosa infection in a Japanese hospital.
    Sasaki M; Hiyama E; Takesue Y; Kodaira M; Sueda T; Yokoyama T
    J Hosp Infect; 2004 Feb; 56(2):111-8. PubMed ID: 15019222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis.
    Parry MF; Neu HC
    J Infect Dis; 1976 Aug; 134 Suppl():S194-7. PubMed ID: 823276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How and why to monitor Pseudomonas aeruginosa infections in the long term at a cystic fibrosis centre.
    Kalferstova L; Vilimovska Dedeckova K; Antuskova M; Melter O; Drevinek P
    J Hosp Infect; 2016 Jan; 92(1):54-60. PubMed ID: 26597636
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic.
    Jones AM; Govan JR; Doherty CJ; Dodd ME; Isalska BJ; Stanbridge TN; Webb AK
    Lancet; 2001 Aug; 358(9281):557-8. PubMed ID: 11520529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pseudomonas colonization in cystic fibrosis. A study of 160 patients.
    Kulczycki LL; Murphy TM; Bellanti JA
    JAMA; 1978 Jul; 240(1):30-4. PubMed ID: 96277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
    Ratjen F; Brockhaus F; Angyalosi G
    J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity of ceftazidime and other beta-lactam antibiotics against nosocomial strains of Pseudomonas aeruginosa.
    Santos Ferreira MO; Bacelar MJ; Canica MM
    J Int Med Res; 1984; 12(6):356-60. PubMed ID: 6440822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated in Fukushima Prefecture].
    Niitsuma K; Saitoh M; Kojimabara M; Kashiwabara N; Aoki T; Tomizawa M; Maeda J; Kosenda T
    Jpn J Antibiot; 2001 Feb; 54(2):79-87. PubMed ID: 11338681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.